New Delhi, Feb. 11 -- Contract drug manufacturer OneSource Specialty Pharma received approval for its generic version of Ozempic in Saudi Arabia, clearing the path for selling the type-2 diabetes and weight-loss drug with its partner Hikma Pharmaceuticals PLC.

Hikma is OneSource's exclusive commercialization partner for the Middle East and North Africa (MENA). The approval from the Saudi Food and Drug Authority (SFDA) will enable its entry into Saudi Arabia, one of the largest markets for Ozempic and other weight management/loss drugs.

The exclusive partnership will help the company "capitalize on rising demand for this product" and underscores the ambition of both companies to increase access to high-quality affordable generic drug alt...